Global AutismSpectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone,Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult),by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,Middle East, and Africa) was valued at US$ 2,285.5 million in 2019 and is projected to exhibit a CAGR of 10.9% overthe forecast period (2019 - 2027).
Increasing investigationalresearch and funding support for pharmacogenomics-based drug discovery is amajor factor driving growth of the autism spectrum disorder therapeuticsmarket. Various organizations arefocused on receiving approvals to investigate novel drugs for the treatment ofASD. For instance, in January 2018, Roche announced that the U.S. Food and DrugAdministration (FDA) granted breakthrough therapy designation for itsinvestigational oral medicine balovaptan, a vasopressin 1a (V1a) receptorantagonist for individuals with ASD. Balovaptan demonstrated potential toimprove social interaction and communication in people with ASD. Similarly, inMay 2018, the U.S. FDA granted fast track designation for Yamo Pharmaceuticals’investigational drug L1-79, a tyrosine hydroxylase inhibitor intended todiminish the socialization and communication symptoms in individuals with ASD.L1-79 demonstrated potential to address an unmet medical need for treatment ofcore symptoms of ASD.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2643
Increasing funding for theresearch of ASD drugs is expected to contribute in the ASD therapeutics marketsize. For instance, in June 2018, Innovative Medicines Initiative funded US$132 million to a research grant titled Autism Innovative MedicineStudies-2-Trials (AIMS-2-Trials), which is academically co-led by the Instituteof Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College Londonand F. Hoffmann-La Roche, Basel. Manufacturers in the autism spectrum disordertherapeutics market are focused on adopting collaboration and partnershipstrategies to enhance their market share. For instance, in 2017 ServierLaboratories Ltd. and Neurochlore announced signing of an exclusive licensingagreement to develop and market bumetanide for pediatric autism in Europe.Under this agreement, Servier Laboratories Ltd. will develop and market theproduct in Europe and Neurochlore will retain these rights for the U.S. market.
Browse 146 Market Data Tables and30 Figures spread through 308 Pages and in-depth TOC on "Global AutismSpectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone,Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult),by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,Middle East, and Africa) - Global Forecast to 2027"
Furthermore, governmentorganizations are focused on conducting workshops for parents and caregivers ofchildren with developmental disorders, which is expected to aid in the ASDtherapeutic market growth. For instance, a workshop jointly led by Pan AmericanHealth Organization, World Health Organization, and Autism Speaks is organizedannually in the month of August in Buenos Aires, Argentina, to teach skills andraise awareness about autism and its preventive measures.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/autism-spectrum-disorder-therapeutics-market-2643
Key Takeaways of the AutismSpectrum Disorder Therapeutics Market:
The global autism spectrumdisorder therapeutics market is expected to witness a CAGR of 10.9% during theforecast period (2019–2027), owing to increasing drug approvals,investigational studies, and funding
Among drug type, the Aripiprazolesegment is expected to hold major revenue share in 2019-2027, owing toincreasing production of generics of Aripiprazole. For instance, in April 2015,the U.S. Food and Drug Administration (FDA) approved the pharmaceuticalcompanies Alembic, Hetero Labs, Teva, and Torrent for manufacturing the genericversion of Bristol-Myers Squibb’s Abilify oral tablets.
Major players operating in theglobal autism spectrum disorder therapeutics market include, F. Hoffmann-LaRoche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, ServierLaboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon GenomicsS.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., ZynerbaPharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and BristolMyers Squibb.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2643
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
